The management of benign and malignant pheochromocytoma and abdominal paraganglioma

European Journal of Surgical Oncology

Volumn 29, Issue 3, 2003, Pages 278-283

  Edström Elder, Elisabeth ^a   Skog, A H Hjelm ^a   Hoog A ^a   Hamberger, B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adrenal tumour; Follow up; Paraganglioma; Pheochromocytoma

Indexed keywords

ADENOSINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; IODINE 131; PHENOXYBENZAMINE; VINCRISTINE;

ABDOMINAL TUMOR; ADULT; ARTICLE; BENIGN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; METASTASIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR CLASSIFICATION; TUMOR RECURRENCE; VALIDATION PROCESS;

EID: 0345073639     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1413     Document Type: Article

References (27)

1. Lack EE. Tumours of the adrenal gland and extra-adrenal paraganglia. Washington, D.C.: Armed Forces Institute of Pathology; 1997.
2. Kenady DE, McGrath PC, Sloan DA, Schwartz RW. Diagnosis and management of pheochromocytoma. Curr Opin Oncol 1997; 9: 61-7.
3. Tischler A. The adrenal medulla and extra-adrenal paraganglia. In: Kovacs K, Asa S (eds). Functional endocrine pathology. Oxford: Blackwell Scientific; 1998: 550-95.
4. Medeiros LJ, Wolf BC, Balogh K, Federman M. Adrenal pheochromocytoma: a clinicopathologic review of 60 cases. Hum Pathol 1985; 16: 580-9.
5. Solcia EKG, Sobin LH (eds). Histological Typing of Endocrine Tumours (2nd edn). Berlin: Springer, 2000.
6. van Heerden JA, Sheps SG, Hamberger B, Sheedy PF, 2nd, Poston JG, ReMine WH. Pheochromocytoma: current status and changing trends. Surgery 1982; 91: 367-73.
7. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treat ment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109: 267-73.
8. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology 1999; 53: 679-83.
9. Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001; 127: 143-55.
10. Gröndal S, Bindslev L, Sollevi A, Hamberger B. Adenosine: a new antihypertensive agent during pheochromocytoma removal. World J Surg 1988; 12: 581-5.
11. Edström E, Gröndal S, Norström F et al. Long term experience after subtotal adrenalectomy for multiple endocrine neoplasia type IIa. Eur J Surg 1999; 165: 431-5.
12. Proye CA, Vix M, Jansson S, Tisell LE, Dralle H, Hiller W. 'The' pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg 1994; 18: 467-72.
13. Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229: 755-64.
14. Mornex R, Badet C, Peyrin L. Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990. J Endocrinol Invest 1992; 15: 643-9.
15. Jansson S, Tisell LE, Hansson G, Stenstrom G. Multiple neuroectodermal abnormalities in pheochromocytoma patients. World J Surg 1988; 12: 710-7.
16. Orchard T, Grant CS, van Heerden JA, Weaver A. Pheochromocytoma - continuing evolution of surgical therapy. Surgery 1993; 114: 1153-8.
17. Geoghegan JG, Emberton M, Bloom SR, Lynn JA. Changing trends in the management of phaeochromocytoma. Br J Surg 1998; 85: 117-20.
18. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). World J Surg 1990; 14: 325-9.
19. Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997; 29: 1133-9.
20. Gupta D, Shidham V, Holden J, Layfield L. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-I, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl Immunohistochem Molecul Morphol 2000; 8: 267-74.
21. van der Harst E, Bruining HA, Jaap Bonjer H et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 2000; 191: 175-80.
22. Salmenkivi K, Arola J, Voutilainen R et al. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab 2001; 86: 2231-5.
23. Edström Elder E, Xu D, Höög A et al. Ki-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 2002 (submitted).
24. Schlumberger M, Gicquel C, Lumbroso J et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992; 15: 631-42.
25. Sisson JC, Shapiro B, Shulkin BL, Urba S, Zempel S, Spaulding S. Treatment of malignant pheochromocytomas with 131-1 metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol 1999; 22: 364-70.
26. Krempf M, Lumbroso J, Mornex R et al. Use of m-[1311]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 1991; 72: 455-61.
27. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (1311-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997; 20: 648-58.